According to Vericel
's latest financial reports the company has $0.10 B in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2023-12-31 | $0.10 B | -8.35% |
2022-12-31 | $0.11 B | 15.61% |
2021-12-31 | $0.10 B | 36.4% |
2020-12-31 | $75.8 M | 8.73% |
2019-12-31 | $69.71 M | -15.93% |
2018-12-31 | $82.92 M | 208.7% |
2017-12-31 | $26.86 M | 16.9% |
2016-12-31 | $22.97 M | 57.59% |
2015-12-31 | $14.58 M | -51.95% |
2014-12-31 | $30.34 M | 276.51% |
2013-12-31 | $8.05 M | -40.91% |
2012-12-31 | $13.63 M | 146.62% |
2011-12-31 | $5.53 M | -82.3% |
2010-12-31 | $31.24 M | |
2010-06-30 | $19.11 M | 12.46% |
2009-06-30 | $17 M | -24.32% |
2008-06-30 | $22.46 M | -20.7% |
2007-06-30 | $28.32 M | -34.12% |
2006-06-30 | $42.99 M | 32.65% |
2005-06-30 | $32.41 M | 91.5% |
2004-06-30 | $16.92 M | 61.02% |
2003-06-30 | $10.51 M | 9.44% |
2002-06-30 | $9.6 M | -9.89% |
2001-06-30 | $10.65 M |
Company | Cash on Hand | differencediff. | Country |
---|---|---|---|
Royalty Pharma RPRX | $1.23 B | 1,026.13% | ๐ฌ๐ง UK |
Neogen NEOG | $0.16 B | 53.75% | ๐บ๐ธ USA |